MRK
Merck & Co., Inc.
NYSE: MRK · Rahway, NJ · Healthcare
$119.60+0.08 (+0.07%)Closed
Market Cap$295.34B
Cash$5.70Bmost recent
Runwayprofitable
P/E (TTM)16.4EPS $7.28
52-Wk Range$76.14 – $123.18
Avg Volume12.5M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$119.60-2.9%
Pipeline

Drug candidates sponsored by Merck & · ClinicalTrials.gov

89 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Remicade
Spondylitis, Ankylosing
Completed
2005-10-01past
1
Phase 4sisomicin
Pyoderma
Withdrawn—1
Phase 3Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Measles+3 more
Completed
2001-05past
1
Phase 3MK0869, aprepitant
Postoperative Nausea and Vomiting
Completed
2004-11-24past
1
Phase 3AzaSite
Bacterial Conjunctivitis
Completed
2005-10past
1
Phase 3MK0826, ertapenem sodium / Duration of Treatment: 14 Days
Infection+2 more
Completed
2006-01past
1
Phase 3Rocuronium bromide (Zemuron)
Anesthesia
Completed
2007-07past
1
Phase 3MK0974 50 mg
Migraine
Completed
2007-12past
1
Phase 3ProQuad®
Varicella+9 more
Completed
2008-03-27past
1
Phase 3pneumococcal 23v polysaccharide vaccine
Pneumococcal Infection
Completed
2008-05past
1
Phase 3Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)
Hepatitis C, Chronic
Completed
2008-05past
1
Phase 3sugammadex
Neuromuscular Blockade
Completed
2009-07past
1
Phase 3Saizen® A
Children Born With Serious Intra-uterine Growth Retardation
Completed
2010-02past
1
Phase 3Peginterferon alfa-2b (PEG)
Hepatitis C, Chronic
Completed
2010-05past
1
Phase 3Sitagliptin phosphate
Type 2 Diabetes
Completed
2010-10-04past
1
Phase 3Sitagliptin
Type 2 Diabetes Mellitus
Completed
2010-11-10past
1
Phase 3Boceprevir
Chronic Hepatitis C Genotype 1
Completed
2013-10-21past
1
Phase 3ertapenem sodium
Infection+2 more
Completed
2013-12-08past
2
Phase 3Anacetrapib
Hyperlipoproteinemia Type II+1 more
Terminated
2014-06past
1
Phase 39vHPV Vaccine
Genital Warts+2 more
Completed
2014-08-04past
1
Phase 3V260
Rotavirus Gastroenteritis
Completed
2015-06-11past
1
Phase 3Daptomycin
Acute Hematogenous Osteomyelitis+1 more
Completed
2016-06-14past
2
Phase 3GONAL-f®
Infertility+3 more
Completed
2017-03-16past
2
Phase 3Belzutifan
Carcinoma, Renal Cell+2 more
Recruiting
2026-10-28
3
Phase 3Pembrolizumab
Urothelial Carcinoma Associated 1 RNA, Human+28 more
Recruiting
2027-05-04
4
Phase 3Cladribine Low Dose
Generalized Myasthenia Gravis
Recruiting
2028-08-23
1
Phase 3Sacituzumab tirumotecan
Bladder Cancer+3 more
Recruiting
2029-07-27
2
Phase 3Indinavir sulfate
HIV Infections
Completed—1
Phase 2MK0777
Generalized Anxiety Disorder
Completed
2003-02past
1
Phase 2PegIntron (peginterferon alfa-2b)
Hepatitis C, Chronic+1 more
Completed
2006-07past
1
Phase 2epinastine 0.1%
Allergic Rhinitis
Completed
2006-10past
1
Phase 2MK3207- 2.5 mg
Migraine
Completed
2009-01past
1
Phase 2MK-5442
Osteoporosis
Terminated
2010-12past
1
Phase 2CXA-101/ tazobactam and metronidazole
Complicated Intra-abdominal Infection
Completed
2011-02-20past
1
Phase 2SCH 727965
Breast Neoplasms+1 more
Completed
2011-06past
1
Phase 2Posaconazole
Mycoses+1 more
Completed
2012-11-20past
2
Phase 2Preladenant
Parkinson's Disease
Completed
2013-06-01past
1
Phase 2ridaforolimus
Endometrial Cancer+1 more
Completed
2013-12past
2
Phase 2Caspofungin
Candidiasis, Invasive
Terminated
2018-01-02past
1
Phase 2V114 Lot 1
Pneumococcal Infections
Completed
2018-10-04past
1
Phase 2Part A: RPL554
Pulmonary Disease, Chronic Obstructive
Completed
2019-05-23past
1
Phase 2Elpipodect
Schizophrenia
Completed
2024-06-21past
1
Phase 2Pembrolizumab/Vibostolimab Co-Formulation
Uterine Cervical Neoplasms+10 more
Completed
2025-08-05past
1
Phase 2Efinopegdutide
Non-alcoholic Fatty Liver Disease+4 more
Completed
2025-12-29past
1
Phase 2favezelimab/pembrolizumab
Solid Tumor+2 more
Completed
2026-03-12past
1
Phase 2Posaconazole IV 6 mg/kg
Invasive Fungal Infection
Recruiting
2026-12-16
1
Phase 2Sotatercept
Pulmonary Arterial Hypertension
Active, not recruiting
2028-06-16
1
Phase 2Doravirine
Human Immunodeficiency Virus (HIV) Infection
Recruiting
2028-11-12
1
Phase 1Opevesostat
Prostatic Neoplasms, Castration-Resistant
Recruiting
2029-01-15
1
Phase 2MK-2214
Early Alzheimer's Disease
Recruiting
2029-04-30
1
Phase 1coformulation pembrolizumab/quavonlimab
Small Cell Lung Carcinoma
Active, not recruiting
2029-12-10
1
Phase 2MK-1084
Malignant Neoplasm
Recruiting
2033-01-14
1
Phase 1Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
Infertility Implantation Failure
Completed—1
Phase 1EMD 72000 (matuzumab) + ECX
Esophageal Cancer+1 more
Completed
2006-05past
1
Phase 1Placebo
Glaucoma
Completed
2009-05past
1
Phase 1ACE-031
Muscle Loss
Completed
2009-07past
1
Phase 1MK-3614
Hypertension
Completed
2009-12-09past
1
Phase 1Hydrochlorothiazide (HCTZ)
Hypertension
Completed
2010-02past
1
Phase 1dalotuzumab (MK0646)
Breast Cancer
Completed
2010-02-17past
1
Phase 1EMD 1201081 + 5-FU + Cisplatin + Cetuximab
Squamous Cell Carcinoma of the Head and Neck
Terminated
2011-04past
1
Phase 1Oxyntomodulin
Type 2 Diabetes Mellitus
Completed
2011-07past
1
Phase 1MK-1972
HIV-1 Infection
Terminated
2012-01-03past
1
Phase 1MSB0010841
Psoriasis
Completed
2015-08past
1
Phase 1V920 Vaccine
Ebola Virus
Completed
2016-06-23past
1
Phase 1Birabresib Dose 20 mg
AML Including AML de Novo and AML Secondary to MDS+1 more
Terminated
2018-01-18past
1
Phase 1Peposertib
Healthy
Completed
2021-03-03past
1
Phase 1Islatravir
Human Immunodeficiency Virus (HIV) Infection
Completed
2021-09-13past
1
Phase 1MK-4318
Healthy+1 more
Completed
2024-04-11past
1
Phase 1MK-6552
Healthy
Completed
2024-09-27past
1
Phase 1MK-4830
Neoplasms
Completed
2025-09-26past
1
Phase 1MK-4700
Malignant Neoplasm
Completed
2025-12-08past
1
Phase 1M9140
Solid Tumors+1 more
Active, not recruiting
2026-09-30
1
Phase 1Fluzone HD influenza vaccine
Healthy Participants
Active, not recruiting
2026-12
1
N/AUnnamed
Osteoporosis
Completed
2005-06past
1
N/AUnnamed
Non-alcoholic Fatty Liver Disease (NAFLD)
Completed
2010-07past
1
N/AUnnamed
Neuromuscular Blockade
Completed
2010-11past
1
N/ARecombinant human follicle stimulating hormone (r-hFSH)
Infertility
Completed
2011-07past
1
N/AUnnamed
Alzheimer's Disease
Completed
2011-09past
1
N/AInfliximab
Psoriasis
Completed
2011-10past
1
N/ARotavirus Vaccine
Pediatric Gastroenteritis
Terminated
2011-11past
1
N/AUnnamed
Multiple Sclerosis, Relapsing-Remitting
Completed
2012-09past
1
N/APosaconazole oral suspension 40 mg/mL
Fungal Infections
Completed
2013-11past
1
N/AUnnamed
Obesity, Morbid+1 more
Completed
2014-11past
1
N/ASimponi®
Arthritis, Rheumatoid+2 more
Completed
2015-09past
1
N/AUnnamed
Growth Disorders
Completed
2015-12-31past
1
N/AUnnamed
Growth Disorders
Completed
2015-12-31past
1
N/APergoveris®
Infertility
Completed
2018-05-10past
1
N/AUnnamed
Non-Obstructive Coronary Artery Disease
Completed
2018-07-11past
1
N/AMavenclad
Multiple Sclerosis
Active, not recruiting
2029-01-31
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for MRK. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.